About
Modulating Immune and Inflammatory Disease by Preventing Myeloid Cells from Entering Inflamed Tissue
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. The company's Monocyte Targeting Technology (MTT) is designed to selectively block the migration of monocytes from the blood stream into inflamed tissues. With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, The company is advancing its solution (IW-601) to a Ph1 clinical trial.
Identity
| Name | ImmuneWalk Therapeutics |
|---|---|
| Slug | immunewalk-therapeutics |
| Type / kind | startup |
| Source _id | XVm81CSwc0jRTs8Rxub3ByRCmjAMa1UyCMCULORW2To9jSfcDY9RLo |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Petah Tikva |
| HQ address | Petah Tikva, Israel |
Web & social
| Website | https://immunewalk.com/ |
|---|---|
| Twitter / X | https://x.com/immunewalk |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical Biotechnology
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business models
B2C
Tags
immuno-theraphybiopharmaceutical
Funding
| Total raised | $7.0M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}